Observed antagonistic effect of linezolid on daptomycin or vancomycin activity against biofilm-forming methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model by Luther, Megan & LaPlante, Kerry L
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2015
Observed antagonistic effect of linezolid on
daptomycin or vancomycin activity against biofilm-
forming methicillin-resistant Staphylococcus aureus
in an in vitro pharmacodynamic model
Megan Luther
University of Rhode Island
Kerry L. LaPlante
University of Rhode Island, kerrylaplante@uri.edu
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Luther, M. & LaPlante, K. L. (2015). Observed antagonistic effect of linezolid on daptomycin or vancomycin activity against biofilm-
forming methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy,
59(12), 7790-7794. doi: 10.1128/AAC.01604-15
Available at: http://dx.doi.org/10.1128/AAC.01604-15
1 
 
Title: Observed antagonistic effect of linezolid on daptomycin or vancomycin activity against 1	  
biofilm-forming methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic 2	  
model 3	  
 4	  
Date August 19, 2015  5	  
Running title: Linezolid antagonism of cell wall active agents 6	  
 7	  
Megan Luther1,2 and Kerry L. LaPlante1,2,3#   8	  
1. Rhode Island Infectious Diseases (RIID) Research Program, Veterans Affairs Medical Center, 9	  
Providence, RI  10	  
2. Department of Pharmacy Practice, University of Rhode Island, Kingston, RI 11	  
3. Warren Alpert Medical School, Brown University, Providence, RI 12	  
 13	  
#Corresponding Author: Kerry L. LaPlante, Pharm.D., Professor of Pharmacy, University of 14	  
Rhode Island, Department of Pharmacy Practice;  Senior Director, RIID Research Program, 15	  
Providence Veterans Affairs Medical Center; Adjunct Associate Professor of Medicine, Brown 16	  
University; University of Rhode Island, College of Pharmacy; 7 Greenhouse Road; Kingston, RI 17	  
02881; office: 401.874.5560; fax: 401.874.2717; email: KerryLaPlante@uri.edu 18	  
 19	  
  20	  
2 
 
ABSTRACT 21	  
Pharmacodynamic activity in antibiotic combinations of daptomycin, vancomycin and linezolid 22	  
was investigated in a 48h in vitro pharmacodynamic model. Using free human-simulated 23	  
concentrations, activity against clinical biofilm-forming methicillin-resistant Staphylococcus 24	  
aureus isolates was evaluated. Linezolid antagonized vancomycin activity at 24 and 48h. 25	  
Linezolid antagonized daptomycin at 24 and 48h depending on dose and strain. Adding 26	  
daptomycin increased vancomycin activity at 48h (p<0.03). These results may be strain-27	  
dependent and require further clinical investigation.  28	  
 29	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There is recent increased interest in the activity of protein synthesis inhibitors in combination 32	  
with cell wall active agents. Some combination regimens are being used clinically, but are 33	  
lacking data to support their combined use.(1) High-dose daptomycin and linezolid have been 34	  
recommended for use as combination therapy in the 2011 methicillin-resistant Staphylococcus 35	  
aureus (MRSA) treatment guidelines for persistent bacteremia or vancomycin failure.(2)  36	  
However, other in vitro studies have demonstrated antagonism with combinations of linezolid 37	  
and vancomycin.(3, 4)  To date, there have been limited investigations with daptomycin and 38	  
linezolid in combination.(5, 6) The combined use of these agents prompted an investigation into 39	  
pharmacokinetic/pharmacodynamic activity and possible interactions when using combinations 40	  
of bactericidal and bacteriostatic antimicrobials, as previously described.(7, 8)  41	  
 42	  
Two randomly selected clinical MRSA blood isolates (L31 and L328) from the LaPlante 43	  
Laboratory at the Providence Veterans Affairs Medical Center were selected for analysis.  Both 44	  
are known biofilm-producing strains, previously isolated from patients with catheter-related 45	  
bloodstream infections.(9) Biofilm formation was previously determined as described.(9, 10) 46	  
Daptomycin (lot# CDC271; Cubist Pharmaceuticals, Inc., Lexington, MA), linezolid (lot# 47	  
11C10U10, 13F05U09; Pfizer, New York, NY), and vancomycin (lot# 12070DD, 382553A; 48	  
Hospira, Lake Forest, IL) were tested.  Mueller-Hinton broth (MHB, Becton Dickinson, Sparks, 49	  
MD, USA) supplemented with calcium and adjusted to 25 mg/L calcium chloride (for daptomycin 50	  
studies 50mg/mL of calcium chloride; ionized Ca; 1.03-1.23 mmol/L) and 12.5 mg/L magnesium 51	  
was used for all minimum inhibitory concentrations (MICs), minimum bactericidal concentrations 52	  
(MBCs), and in vitro pharmacodynamic (IVPD) infection models.(11-13)  Colony counts were 53	  
determined using Tryptic Soy Agar (TSA, Difco, Becton Dickinson).  54	  
 55	  
A previously described IVPD model was used to evaluate several antibiotic regimens against 56	  
MRSA.(7)  Briefly, a 0.5 McFarland standard of planktonic bacteria from overnight growth on 57	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TSA was diluted in a one compartment model (250ml working volume) to a starting inoculum of 58	  
~106 CFU/mL. Free concentrations of antimicrobials were evaluated. Daptomycin was 59	  
administered to simulate a 6mg/kg dose (t1/2 8h, Cmax 98.6µg/mL, protein-binding 92%; fCmax 60	  
7.9µg/mL) or 10mg/kg dose (t1/2 8h, Cmax 140µg/mL, protein binding 92%; fCmax 11.2µg/mL) 61	  
every 24 hours(q24h), (14); linezolid 600mg q12h, (t1/2 6hrs, Cmax 21ug/mL, protein-binding 62	  
31%; fCmax 14.5µg/mL) (15); and vancomycin 1.25g q12h (t1/2 6hrs, Cmax 45µg/mL, Cmin 15-63	  
20 µg/mL, protein binding 55%; fCmax 20.3µg/mL). (16) Antibiotics were given as boluses into 64	  
the compartment and peristaltic pumps were used to achieve the desired half-lives and replace 65	  
media with fresh MHB. All model experiments were performed in duplicate to triplicate to ensure 66	  
reproducibility. In addition, simulations in the absence of antibiotics were performed to assure 67	  
adequate growth of organisms in the model. Samples were removed from each model at each 68	  
0, 4, 8, 24, 32 and 48 hour time point. Once removed, samples were immediately diluted, plated 69	  
on TSA, and incubated at 37oC for 24h before colony count enumeration.  The limit of detection 70	  
for this method is 2.0 log10 CFU/mL.(17) Antimicrobial carryover was minimized by serial dilution 71	  
(1:10-1:10,000) of plated samples in conjunction with vacuum filtration, if needed, as previously 72	  
described.(12) 73	  
 74	  
MICs and MBCs of study antimicrobial agents were determined by Etest methodology and broth 75	  
microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines.(18, 19)  76	  
All samples were incubated at 37°C in ambient air for 24 hours.  E-tests were used to assess 77	  
changes in MIC at 24 and 48h to detect resistance. Plates were examined for growth after 24h 78	  
of incubation at 37oC.  Changes in MIC were confirmed with microbroth dilution MIC. Samples 79	  
were evaluated directly from the model to prevent changes in MIC from removing antibiotic 80	  
pressure and to optimize the detection of MIC changes.   81	  
 82	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Time-kill curves were plotted to determine reduction in log10 CFU/mL over 48 hours. Bactericidal 83	  
activity (99.9% kill) was defined as a ≥ 3 log10 CFU/mL reduction and bacteriostatic activity was 84	  
defined as a < 3 log10 CFU/mL change in colony count from the initial inoculum.(20) The time to 85	  
kill 99.9% of the bacteria present was determined by non-linear regression (using a minimum of 86	  
4 data points) if r2 ≥ 0.95 or by visual inspection. Enhancement of activity was defined as an 87	  
increase in kill of ≥ 2-log10 CFU/mL by combination of antimicrobials versus the most active 88	  
single agent of that combination.(7)  Improvement was defined as a 1 to 2-log10 CFU/mL 89	  
increase in kill in comparison to the most active single agent, while combinations that resulted in 90	  
≥ 1-log10 bacterial growth in comparison to the most active single agent were considered to 91	  
represent antagonism.(7) The terms “improvement” and “enhancement” were used because our 92	  
simulations involve therapeutically obtained serum concentration and this does not permit the 93	  
mathematical modeling necessary to consider the standard terms “additivity” and “synergy” (7, 94	  
21).  Indifference was defined as <1-log10 CFU/mL change in activity.   95	  
 96	  
Samples for pharmacokinetic analyses were obtained through the injection port at 0, 0.5, 1, 2, 4, 97	  
6, 8, and 24h for verification of target antibiotic concentrations.  All samples were stored at         98	  
-80oC until analysis.  Daptomycin concentrations were determined by a previously described 99	  
and validated HPLC method (Center for Anti-Infective Research and Development, Hartford, 100	  
CT).(11) Vancomycin concentrations were determined by a homogeneous particle-enhanced 101	  
turbidmetric immunoassay (PETIA; Architect, Multigent®; Abbott Diagnostics Abbott Park, IL, 102	  
USA) at the Providence Veteran Affairs Medical Center.(11)  The vancomycin assay has a 103	  
detection range of 0.5 to 80.0 µg/mL, and a between day sample precision and CV% of 1.6% 104	  
and < 5.0%, respectively. Linezolid concentrations were evaluated using HPLC (Infectious 105	  
Disease Pharmacokinetics Laboratory; Charles Peloquin) as previously described.(7)  The half-106	  
life, AUC, Cmax, and minimum concentration (Cmin) of the antibiotics were determined by the 107	  
trapezoidal method utilizing PK Analyst software (Version 1.10, MicroMath Scientific Software, 108	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Salt Lake City, UT).  Maximum concentration (Cmax) to MIC ratios, the percent time above the 109	  
MIC (%T > MIC), and AUC0-24 to MIC ratios were calculated for each antibiotic and were 110	  
compared to literature values.(22-25) 111	  
 112	  
Changes in bacterial growth (log10 CFU/mL) at 4, 8, 24 and 48h and time to 99.9% kill were 113	  
compared by analysis of variance with Tukey’s post-hoc test. A p value of < 0.05 was 114	  
considered significant.(7, 11) All statistical analyses were performed using SPSS Statistical 115	  
Software (Release 20 SPSS, Inc., Chicago, IL). 116	  
 117	  
The MIC results are shown with MBCs and pharmacodynamic parameters obtained in Table 1.  118	  
Pharmacokinetic values obtained were within 8% of targeted values.  The results of the IVPD 119	  
models are demonstrated in Figure 1 and Table 2.  120	  
 121	  
Against both biofilm-forming isolates, all regimens, including monotherapy and combination, 122	  
demonstrated statistically significant kill (decrease in CFU/mL) by 8 hours as compared to 123	  
growth control (p<0.001). Linezolid demonstrated initial kill until 24h, with regrowth until 48h. 124	  
Vancomycin demonstrated bacteriostatic activity at 24h against L31, but bactericidal activity 125	  
against L328 at 24h. Vancomycin was bacteriostatic at 48h against both isolates. No increases 126	  
in MIC were found at 24 or 48h in any of the experiments.  127	  
 128	  
For both isolates, daptomycin at 6mg/kg and 10mg/kg demonstrated bactericidal activity by 24h. 129	  
Daptomycin and vancomycin plus daptomycin were the only regimens to demonstrate sustained 130	  
bactericidal activity from 24 to 48h. Daptomycin alone was significantly more active than 131	  
linezolid at 48h (mean differences in log CFU/mL 1.78-2.73, p<0.04).  132	  
 133	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In combination studies, at 24h vancomycin plus daptomycin 6mg/kg and daptomycin 6mg/kg or 134	  
10mg/kg plus linezolid were not statistically significantly different from their most active 135	  
components. This is despite meeting the definition for antagonism against both isolates for 136	  
daptomycin 10mg/kg plus linezolid, and L328 for daptomycin 6mg/kg plus linezolid. Linezolid 137	  
plus vancomycin was the least active regimen. Linezolid plus vancomycin met the definition for 138	  
antagonism at 24h for both isolates, but was significantly different only for L328 (1.67, 95%CI 139	  
0.76-2.59, p<0.01).  140	  
 141	  
Linezolid plus daptomycin 6mg/kg met the definition for antagonism at 24h for one isolate and 142	  
48 hours for both isolates, while the higher dose of daptomycin plus linezolid demonstrated 143	  
antagonism at 24h for both isolates and 48h for one. Against L31, the activity of daptomycin 144	  
6mg/kg or 10mg/kg alone was significantly greater than daptomycin (either dose) plus linezolid 145	  
at 48h (mean difference in log CFU/mL 1.82-2.43, p<0.01). The differences in activity between 146	  
linezolid containing regimens (linezolid alone, linezolid plus vancomycin, daptomycin plus 147	  
linezolid) were not statistically significant at 48h for both isolates, but linezolid alone was less 148	  
active than either dose of daptomycin alone (mean differences 1.78-2.73, p<0.04). Adding 149	  
daptomycin 6mg/kg improved the activity of vancomycin at 48h (mean difference in log CFU/mL 150	  
1.65-2.20, p<0.03), but was not significantly different than daptomycin alone.    151	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Despite common concomitant clinical use of linezolid with bactericidal antibiotics,(1) we have 152	  
demonstrated in vitro antagonism at 24 and 48h using combinations of linezolid plus 153	  
vancomycin and linezolid plus daptomycin.  The use of these combinations of antibiotics is 154	  
lacking both in vitro and clinical outcomes data to support their use.  Combinations of two active 155	  
antibiotics are frequently excluded or not analyzed in clinical trials where single agents are the 156	  
main focus, due to small numbers of patients.(1, 26)  Notably, a landmark study by Lepper et al. 157	  
demonstrated an increase in mortality in meningitis patients receiving tetracycline-penicillin 158	  
combination therapy over patients receiving the same penicillin dose alone.(27) The stasis 159	  
produced by protein synthesis inhibitors, including linezolid, likely inhibits the activity of cell wall 160	  
active antibiotics, which work best on actively-dividing bacteria. Antagonism has been 161	  
demonstrated in previous time-kill studies using static concentrations of combinations of 162	  
vancomycin and linezolid.(3-6) Linezolid has also demonstrated attenuation of activity of 163	  
aztreonam or ceftazidime against Escherichia coli isolates in an in vitro pharmacodynamic 164	  
model.(7) This highlights the importance of pharmacodynamic interactions with combination 165	  
therapy, even for antibiotics with a completely different spectrum of activity.  Of interest, one 166	  
study has demonstrated activity of daptomycin and linezolid in combination against MRSA, but 167	  
in contrast to our study, this study tested formed biofilms on coupons.(28)  168	  
 169	  
In our study, regrowth was noted between 24 and 48h for both strains though no increases in 170	  
MIC were noted using Etests.  This could be due to biofilm formation of these planktonic strains 171	  
after 24h, increasing growth without susceptibility changes, since biofilms can withstand 10-172	  
1000 times the concentrations of antibiotics compared to planktonic bacteria. According to 173	  
research by our group, approximately 50% of MRSA isolates from our institution form 174	  
biofilm.(29)  Biofilm-forming isolates are known to cause persistent, difficult to treat infections 175	  
where combination therapy may be considered. The strains used in this study previously tested 176	  
positive for biofilm formation as noted above, using the same temperature and inoculum, with 177	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similar media to this IVPD model. Over the 48h period tested, biofilm growth could seed 178	  
susceptible bacteria into the model during sampling, which would appear as regrowth.(9) A 179	  
previous study demonstrated a reduction in biofilm biomass, but no reduction in cell viability, 180	  
using combinations of linezolid and vancomycin against formed MRSA biofilms.(30)  181	  
 182	  
Despite reaching the target of the estimated total AUC/MIC ratio for vancomycin of >400, and 183	  
with an estimated total vancomycin trough concentration of 15.5µg/mL, vancomycin did not 184	  
achieve bactericidal activity against L31 during the 48h period. This indicates that for an isolate 185	  
with a vancomycin MIC of 2mg/L, this regimen may not be adequate. 186	  
 187	  
In regard to limitations, we evaluated two strains, and recognize that these observations may be 188	  
isolate-specific or dependent on the MICs of the isolates for each antibiotic.  189	  
 190	  
In these daptomycin-, linezolid-, and vancomycin-susceptible strains of biofilm-forming MRSA, 191	  
regimens containing daptomycin were more active than those containing linezolid. Linezolid 192	  
antagonized the activity of vancomycin and daptomycin 6 mg/kg and 10mg/kg at 24 and 48h. 193	  
Adding linezolid to daptomycin 6mg/kg or 10mg/kg significantly decreased activity at 48h 194	  
against L31 versus daptomycin alone. The combination of vancomycin plus daptomycin 6mg/kg 195	  
or daptomycin 6mg/kg or 10mg/kg alone demonstrated sustained bactericidal activity through 196	  
the 48h period. Based on this data, combinations of linezolid with either daptomycin 6mg/kg, 197	  
10mg/kg or vancomycin should be investigated for the clinical implications of in vitro 198	  
antagonism.   199	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 314	  
 
MIC 
(mcg/mL) 
MBC 
(mcg/mL) 
fCmax/ MIC %T>MIC fAUC/MIC 
Estimated 
totalAUC/MIC 
MRSA (L31)       
Daptomycin 
(6mg/kg) 
0.5 1 17.13 ± 0.61 100% 170-181 2121-2262 
Linezolid 1 >64 14.49 ± 0.66 100% 213 309 
Vancomycin 2 2 10.77 ± 1.23 100% 181-185 402-411 
MRSA (L328)       
Daptomycin 
(6mg/kg) 
0.25 0.25 34.26 ± 1.22 100% 339-361 4243-4524 
Linezolid 2 >64 7.24 ± 0.33 100% 107 155 
Vancomycin 1 1 21.55 ± 2.45 100% 362-370 804-823 
 315	  
 316	  
Table 1. MIC, MBC and pharmacodynamic parameters obtained from IVPD experiments using 317	  
free concentrations.  318	  
MIC= minimum inhibitory concentration 319	  
MBC= minimum bactericidal concentration 320	  
fCmax= maximum free concentration 321	  
AUC= area under the curve 322	  
%T>MIC= percentage of time above MIC 323	  
  324	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Regimen MRSA 
Strain 
Change in Log10 CFU/mL relative to 0h at: 
24h 48h 
Growth Control L31 +2.52 ± 0.11 +2.37 ± 0.27 
 L328 +2.46 ± 0.23 +3.29 ± 0.29 
    
Daptomycin 6mg/kg L31 -3.51 ± 0.08 -3.03 ± 0.68 
 L328 -3.11 ± 0.32 -3.15 ± 0.28 
    
Daptomycin 10mg/kg L31 -3.54 ± 0.03 -3.48 ± 0.09 
 L328 -3.45 ± 0.11 -3.24 ± 0.56 
    
Linezolid L31 -2.90 ± 0.47 -0.84 ± 0.43 
 L328 -2.82 ± 0.69 -1.51 ± 0.54 
    
Vancomycin L31 -2.85 ± 0.15 -2.02 ± 0.15 
 L328 -3.08 ± 0.52 -1.39 ± 0.57 
    
Daptomycin 6mg/kg 
+ Linezolid 
L31 -2.62 ± 0.80 
(inhibited 0.81 log CFU/mL, 
indifference) 
-1.14 ± 0.68 
(inhibited 1.82 log CFU/mL, 
antagonism) 
 L328 -2.05 ± 0.35 
(inhibited 1.04 log CFU/mL, 
antagonism*) 
-1.62 ± 0.89 
(inhibited 1.52 log CFU/mL, 
antagonism) 
    
Daptomycin 10mg/kg 
+ Linezolid 
L31 -2.55 ± 0.58 
(inhibited 1.14 log CFU/mL, 
antagonism) 
-1.21 ± 0.66 
(inhibited 2.43 log CFU/mL, 
antagonism*) 
 L328 -2.40 ± 0.18 
(inhibited 1.01 log CFU/mL, 
antagonism*) 
-2.35 ± 0.83 
(inhibited 0.85 log CFU/mL, 
indifference) 
    
Linezolid + 
Vancomycin 
L31 -1.88 ± 0.98 
(inhibited 1.00 log CFU/mL, 
antagonism) 
-0.60 ± 0.55 
(inhibited 1.36 log CFU/mL, 
antagonism) 
 L328 -1.43 ± 0.17 
(inhibited 1.67 log CFU/mL, 
antagonism*) 
-0.14 ± 0.17 
(inhibited 1.27 log CFU/mL, 
antagonism*) 
    
Vancomycin + 
Daptomycin 6mg/kg 
L31 -3.57 ± 0.08 
(no change, indifference) 
-3.57 ± 0.08 
(enhanced 0.48 log CFU/mL, 
indifference) 
 L328 -3.51 ± 0.10 
(enhanced 0.43 log CFU/mL, 
indifference) 
-3.51 ± 0.10 
(enhanced 0.39 log CFU/mL, 
indifference) 
 325	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Table 2. Activity of each antibiotic alone and in combination in an IVPD model at 24 and 48h. 333	  
*Significant antagonism from the most active component of the regimen (p<0.05). 334	  
Improvement: 1-2 log10 CFU/mL increase in kill over the most active component. 335	  
Enhancement: >2 log10 CFU/mL increase in kill over the most active component. 336	  
Antagonism: ≥1 log10 CFU/mL increase in growth over the most active component. 337	  
Indifference: <1 log10 CFU/mL change in activity from the most active component. 338	  
 339	  
 340	  
 341	  
Figure 1. Activity of daptomycin and linezolid (A and C), or vancomycin and linezolid (B and 342	  
D)combinations on planktonic MRSA L31 and L328 over 48h.  343	  
GC= growth control, DAP6= daptomycin 6mg/kg, DAP10= daptomycin 10mg/kg, VAN= 344	  
vancomycin, LZD= linezolid 345	  
  346	  
A	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B	  
